Asset Details
Do you wish to reserve the book?
Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients
Do you wish to request the book?
Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients
2005
Overview
Drug-eluting coronary-artery stents are more effective than bare-metal stents in reducing the frequency of coronary restenosis in patients with diabetes. In a randomized, controlled trial in patients with diabetes, the sirolimus-eluting stent was associated with a smaller extent of late luminal loss than was the paclitaxel-eluting stent, suggesting that the risk of restenosis was also reduced.
In patients with diabetes, the sirolimus-eluting stent was associated with a smaller extent of late luminal loss than was the paclitaxel-eluting stent, suggesting that the risk of restenosis was also reduced.
Coronary artery disease is a major cause of complications and death among patients with diabetes mellitus.
1
In particular, patients with diabetes are prone to a diffuse and rapidly progressive form of atherosclerosis, which increases their likelihood of requiring revascularization.
2
–
4
Percutaneous coronary intervention and aortocoronary bypass surgery are recommended revascularization strategies for such patients. However, because of the increased risk of restenosis after percutaneous coronary interventions in these patients,
5
–
7
aortocoronary bypass surgery has been considered to be the preferred revascularization strategy for many.
8
,
9
Drug-eluting stents markedly reduce the incidence of restenosis as compared with bare-metal stents, both in . . .
Publisher
Massachusetts Medical Society
Subject
/ Angioplasty, Balloon, Coronary
/ Biological and medical sciences
/ Coronary Disease - mortality
/ Coronary Restenosis - epidemiology
/ Coronary Restenosis - prevention & control
/ Coronary Restenosis - therapy
/ Diabetes Complications - therapy
/ Diabetes. Impaired glucose tolerance
/ Endocrine pancreas. Apud cells (diseases)
/ Etiopathogenesis. Screening. Investigations. Target tissue resistance
/ Female
/ Humans
/ Immunosuppressive Agents - administration & dosage
/ Male
/ Myocardial Infarction - epidemiology
/ Paclitaxel - administration & dosage
/ Sirolimus - administration & dosage
/ Stents
